{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["380"],"submitter":["Mao YP"],"funding":["Natural Science Foundation of Guangdong Province","National Natural Science Foundation of China"],"pubmed_abstract":["<h4>Objectives</h4>To address whether sparing the medial retropharyngeal lymph node (MRLN) region from elective irradiation volume provides non-inferior local relapse-free survival versus standard radiotherapy in patients with nasopharyngeal carcinoma.<h4>Design</h4>Open-label, non-inferiority, multicentre, randomised, phase 3 trial.<h4>Setting</h4>Three Chinese hospitals between 20 November 2017 and 3 December 2018.<h4>Participants</h4>Adults (18-65 years) with newly diagnosed, non-keratinising, non-distant metastatic nasopharyngeal carcinoma without MRLN involvement.<h4>Interventions</h4>Randomisation was done centrally by the Clinical Trials Centre at Sun Yat-sen University Cancer Center. Eligible patients were randomly assigned (1:1; block size of four) to receive MRLN sparing radiothe"],"journal":["BMJ (Clinical research ed.)"],"pagination":["e072133"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9900470"],"repository":["biostudies-literature"],"pubmed_title":["Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial."],"pmcid":["PMC9900470"],"pubmed_authors":["Wang SX","Li JB","Zhang N","Liang SQ","Guo R","Liu X","Tang LL","Luo WJ","Huang SH","Liu LZ","Xie FY","Lv JW","Chen L","Xu C","Li YJ","Zhou GQ","Li WF","Sun Y","Liang XY","Chen YP","Mao YP","Zhang Y","Ma J","Gao TS","Lin L"],"additional_accession":[]},"is_claimable":false,"name":"Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial.","description":"<h4>Objectives</h4>To address whether sparing the medial retropharyngeal lymph node (MRLN) region from elective irradiation volume provides non-inferior local relapse-free survival versus standard radiotherapy in patients with nasopharyngeal carcinoma.<h4>Design</h4>Open-label, non-inferiority, multicentre, randomised, phase 3 trial.<h4>Setting</h4>Three Chinese hospitals between 20 November 2017 and 3 December 2018.<h4>Participants</h4>Adults (18-65 years) with newly diagnosed, non-keratinising, non-distant metastatic nasopharyngeal carcinoma without MRLN involvement.<h4>Interventions</h4>Randomisation was done centrally by the Clinical Trials Centre at Sun Yat-sen University Cancer Center. Eligible patients were randomly assigned (1:1; block size of four) to receive MRLN sparing radiothe","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-05-28T20:15:16.216Z","creation":"2025-04-05T11:23:57.121Z"},"accession":"S-EPMC9900470","cross_references":{"pubmed":["36746459"],"doi":["10.1136/bmj-2022-072133"]}}